Serlo Joni, Tarkkanen Maija, Sampo Mika, Vettenranta Kim, Riikonen Pekka, Helenius Ilkka
Department of Pediatric Orthopedic Surgery, Turku Children's Hospital, Turku, Finland.
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Acta Paediatr. 2015 Jul;104(7):738-45. doi: 10.1111/apa.12986. Epub 2015 Apr 6.
Our aims were to establish the 10-year overall and event-free survival rates among children and adolescents with bone sarcomas in Finland, estimate their respective incidences, evaluate the treatment given and describe the key prognostic factors.
We included 88 patients of <18 years of age diagnosed with a bone sarcoma during 1991-2005 in this retrospective, nationwide and population-based study. Median follow-up time was 12.2 years (range 5.8-20.3 years) for surviving patients.
The overall incidence among children and adolescents was 5.1 per million: 3.6 for osteosarcoma, 1.2 for Ewing's sarcoma and 0.3 for chondrosarcoma. The 10-year event-free and overall survival of those with a localised disease at diagnosis was 69% and 82%, respectively. The overall 10-year survival of those with a metastatic disease at diagnosis was 47%. Prognostic factors for localised disease included an axial versus peripheral primary tumour site in Ewing's sarcoma (p = 0.022) and age at diagnosis in osteosarcoma (p = 0.027).
The 10-year overall survival of children and adolescents diagnosed with a bone sarcoma in Finland during 1991 to 2005 was very good, at 82% if the disease was localised at diagnosis and 47% if it was metastatic at diagnosis.
我们的目的是确定芬兰骨肉瘤患儿及青少年的10年总生存率和无事件生存率，估计其各自的发病率，评估所给予的治疗并描述关键预后因素。
在这项回顾性、全国性、基于人群的研究中，我们纳入了1991年至2005年期间诊断为骨肉瘤的88例18岁以下患者。存活患者的中位随访时间为12.2年（范围5.8 - 20.3年）。
儿童及青少年的总发病率为每百万5.1例：骨肉瘤为3.6例，尤因肉瘤为1.2例，软骨肉瘤为0.3例。诊断时疾病局限的患者10年无事件生存率和总生存率分别为69%和82%。诊断时患有转移性疾病的患者10年总生存率为47%。局限性疾病的预后因素包括尤因肉瘤中轴向与外周原发肿瘤部位（p = 0.022）以及骨肉瘤的诊断年龄（p = 0.027）。
1991年至2005年期间在芬兰诊断为骨肉瘤的儿童及青少年的10年总生存率非常好，诊断时疾病局限的患者为82%，诊断时为转移性的患者为47%。
Zotero 插件